<DOC>
	<DOC>NCT00128245</DOC>
	<brief_summary>This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.</brief_summary>
	<brief_title>Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>History of artificial tear use Moderate to severe signs of dry eye Moderate to severe ocular discomfort Patients with uncontrolled systemic or ocular diseases. Have any history of refractive surgery Use any topical ocular medications other than those dispensed for the study, during the study Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>KCS</keyword>
	<keyword>dry eye</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>Keratoconjunctivitis sicca (dry eye syndrome)</keyword>
</DOC>